ProCE Banner Activity

REDO: Ultra-Low-Dose Rituximab for Continued Treatment of RA in Patients on Stable Treatment With Rituximab

Slideset Download
Conference Coverage
Noninferiority of ultralow-dose rituximab for the treatment of RA could not be established by this protocol

Released: November 15, 2019

Expiration: November 13, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Mallinckrodt Pharmaceuticals